Royal London Asset Management Ltd. lifted its stake in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 10.9% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 177,695 shares of the biopharmaceutical company's stock after buying an additional 17,511 shares during the quarter. Royal London Asset Management Ltd.'s holdings in Royalty Pharma were worth $4,533,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Franklin Resources Inc. raised its stake in shares of Royalty Pharma by 5.0% during the third quarter. Franklin Resources Inc. now owns 1,460,515 shares of the biopharmaceutical company's stock valued at $40,705,000 after purchasing an additional 70,130 shares during the period. Charles Schwab Investment Management Inc. increased its stake in Royalty Pharma by 4.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 3,131,628 shares of the biopharmaceutical company's stock worth $79,888,000 after buying an additional 130,025 shares during the period. Pallas Capital Advisors LLC purchased a new stake in Royalty Pharma during the 4th quarter worth $2,355,000. Jupiter Asset Management Ltd. acquired a new position in Royalty Pharma in the 4th quarter worth $4,950,000. Finally, Allspring Global Investments Holdings LLC boosted its position in Royalty Pharma by 303.4% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 539,995 shares of the biopharmaceutical company's stock valued at $13,926,000 after buying an additional 406,123 shares during the last quarter. 54.35% of the stock is owned by institutional investors and hedge funds.
Royalty Pharma Stock Up 0.3 %
NASDAQ:RPRX traded up $0.09 during mid-day trading on Thursday, reaching $31.65. The stock had a trading volume of 7,555,002 shares, compared to its average volume of 2,917,036. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44. The company has a market capitalization of $18.24 billion, a price-to-earnings ratio of 21.83, a price-to-earnings-growth ratio of 2.31 and a beta of 0.47. Royalty Pharma plc has a 1-year low of $24.05 and a 1-year high of $34.20. The stock's 50 day simple moving average is $32.42 and its two-hundred day simple moving average is $28.80.
Royalty Pharma (NASDAQ:RPRX - Get Free Report) last issued its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 EPS for the quarter, topping the consensus estimate of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. Equities analysts anticipate that Royalty Pharma plc will post 4.49 EPS for the current year.
Royalty Pharma Increases Dividend
The firm also recently announced a quarterly dividend, which was paid on Monday, March 10th. Shareholders of record on Friday, February 21st were paid a dividend of $0.22 per share. This is a positive change from Royalty Pharma's previous quarterly dividend of $0.21. The ex-dividend date was Friday, February 21st. This represents a $0.88 annualized dividend and a yield of 2.78%. Royalty Pharma's payout ratio is presently 60.69%.
Wall Street Analysts Forecast Growth
Separately, TD Cowen raised Royalty Pharma to a "strong-buy" rating in a research report on Tuesday, December 24th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Royalty Pharma presently has a consensus rating of "Buy" and a consensus target price of $41.60.
Check Out Our Latest Stock Analysis on Royalty Pharma
Royalty Pharma Company Profile
(
Free Report)
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.
Featured Articles
Before you consider Royalty Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Royalty Pharma wasn't on the list.
While Royalty Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
